- Initiated by Zanofi’s decision to cut in half the price of Zaltrap after MSKCC said it would not use the drug because it was too expensive, the Health Affairs Blog examines how the “buy and bill” pricing system works, and how it operates in the case of Zaltrap.
- Medgadget reports that IBM’s work with WellPoint and MSKCC on the development of Watson has progressed beyond concept. Now, hospitals and other provider institutions who sign up can buy or rent Watson’s advice from the cloud or their own server.
- The Digital Journal announced that physicians at MSKCC will begin the “first-in-man” drug therapy on mesothelioma patients.
Author Archives: Mark
MSKCC in the News: February 14 – February 20
- Westchester Medical Center (WMC) has announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with MSKCC, whose staff will provide outpatient cancer care and infusion services.
- Dr. Michael J. Morris of MSKCC was quoted in a New York Times article about a new study that found that men with high-risk prostate cancer treated with only 18 months of hormone therapy live just as long as those treated for a more standard 36 months.
MSKCC in the News: January 24 – February 13
- IBM Corp., the health insurer WellPoint Inc. and MSKCC announced two Watson-based applications – one to help diagnose and treat lung cancer and one to help manage health insurance decisions and claims.
- A press release announced that researchers at MSKCC have treated the first patient with a new experimental vaccinia virus-based cancer therapy designed for patients with malignant pleural mesothelioma or non-small cell lung cancer.
- Peter Bach of MSKCC is quoted in a Nature News article about the impact of the economic downturn on US academic medical campuses like the University of California, San Francisco (UCSF).